Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema

Peter A. Campochiaro, Charles C. Wykoff, Howard Shapiro, Roman G. Rubio, Jason S. Ehrlich

Research output: Contribution to journalArticlepeer-review

Abstract

Objective To determine the effect of suppression of vascular endothelial growth factor (VEGF) by monthly injection of ranibizumab on posterior retinal nonperfusion (RNP) in patients with diabetic macular edema (DME). Design Unplanned retrospective analysis of prospectively collected data from 2 randomized, sham injection-controlled, double-masked, multicenter clinical trials. Participants Six hundred sixty-six patients with DME. Methods An independent reading center measured the area of RNP on fluorescein angiograms obtained in the phase 3 RISE and RIDE trials. Main Outcome Measures The percentage of patients with no posterior RNP. Results The percentage of patients with no posterior RNP decreased in the sham group between baseline and month 24, but remained relatively stable in the 2 ranibizumab groups. After month 24, the sham group crossed over to receive monthly injections of ranibizumab 0.5 mg, and the differences between the sham and ranibizumab groups were reduced. The percentage of patients who showed an increase in posterior RNP from baseline increased over time in all 3 groups, but at a faster rate in the sham group, resulting in statistically significant differences at every time point between months 3 (9.6% vs. 18.5%; P = 0.016) and 24 (16.1% vs. 37.6%; P<0.0001) for ranibizumab 0.5 mg versus sham and from months 6 (12.3% vs. 23.0%; P = 0.013) through 24 (15.0% vs. 37.6%; P<0.0001) for ranibizumab 0.3 mg. Initiation of ranibizumab in the sham group at month 24 was followed by reduction in the percentage of patients with an increase in posterior RNP from baseline at months 30 and 36, whereas the 2 ranibizumab groups continued their gradual rise. Conclusions Just as high VEGF levels contribute to progression of retinal nonperfusion in retinal vein occlusion, the same is true in patients with DME, suggesting that regardless of the underlying disease process, high levels of VEGF can cause closure of retinal vessels. However, our data also suggest that VEGF-induced worsening of retinal perfusion in DME is superimposed on another cause of more gradually worsening perfusion, possibly glucotoxicity. Thus, monthly injections of ranibizumab can slow, but not completely prevent, retinal capillary closure in patients with DME.

Original languageEnglish (US)
Pages (from-to)1783-1789
Number of pages7
JournalOphthalmology
Volume121
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • Abbreviations and Acronyms
  • BRVO
  • CRVO
  • DA
  • DME
  • ETDRS
  • Early Treatment Diabetic Retinopathy Study
  • RBZ
  • RNP
  • RVO
  • VEGF
  • branch retinal vein occlusion
  • central retinal vein occlusion
  • diabetic macular edema
  • disc area
  • ranibizumab
  • retinal nonperfusion
  • retinal vein occlusion
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema'. Together they form a unique fingerprint.

Cite this